Open Access

Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study

  • Authors:
    • Yoshiyuki Yamaguchi
    • Yousuke Katata
    • Fuminori Sano
    • Hiroaki Tanioka
    • Makoto Okawaki
    • Masahiro Yamamura
    • Takeshi Nagasaka
  • View Affiliations

  • Published online on: August 24, 2020     https://doi.org/10.3892/mco.2020.2125
  • Article Number: 55
  • Copyright: © Yamaguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

For several years, adoptive immunotherapy (AIT) has been performed using autologous zoledronate‑activated killer (ZAK) cells to develop a novel modality for cancer treatment. In the current study, data from 50 patients with incurable gastric cancer were analyzed. Patients were treated with AIT using intravenous ZAK cells every 3‑4 weeks in combination with chemotherapy of the physician’s choice. The possible clinical benefits were subsequently examined. The median overall survival (OS) time of all patients was 7.5 months. In patients that received 5 or more rounds of treatment, the OS was 13.5 months. Additionally, the OS times of 1st, 2nd or later line chemotherapy with ZAK cell AIT were 27.3 months and 13.3 months, respectively. No objective response was observed and the disease control rate was 67.9%. No severe adverse event was recorded. Functional Assessment of Cancer Therapy‑Biologic Response Modifier analysis revealed possible improvement of quality of life after ZAK cell AIT. Univariate analysis revealed a significant positive association between longer survival times and baseline lymphocyte percentages in white blood cell counts (P<0.001), serum albumin (P=0.001), C‑reactive protein (P=0.006), carbohydrate antigen (CA)19‑9 (P=0.010), neutrophil‑lymphocyte ratio (P<0.001) and Glasgow prognostic score (GPS). Only the GPS value (P=0.024) was a significant survival marker when analyzed using the multivariate Cox proportional hazards model. Although the results cannot provide a definitive conclusion, the current suggested that ZAK cell AIT in combination with chemotherapy is safe, feasible and may be a promising treatment option for patients with incurable gastric cancer. The GPS value at baseline may be a potential biomarker for chemo‑immunotherapy.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 13 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamaguchi Y, Katata Y, Sano F, Tanioka H, Okawaki M, Yamamura M and Nagasaka T: Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study. Mol Clin Oncol 13: 55, 2020
APA
Yamaguchi, Y., Katata, Y., Sano, F., Tanioka, H., Okawaki, M., Yamamura, M., & Nagasaka, T. (2020). Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study. Molecular and Clinical Oncology, 13, 55. https://doi.org/10.3892/mco.2020.2125
MLA
Yamaguchi, Y., Katata, Y., Sano, F., Tanioka, H., Okawaki, M., Yamamura, M., Nagasaka, T."Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study". Molecular and Clinical Oncology 13.5 (2020): 55.
Chicago
Yamaguchi, Y., Katata, Y., Sano, F., Tanioka, H., Okawaki, M., Yamamura, M., Nagasaka, T."Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study". Molecular and Clinical Oncology 13, no. 5 (2020): 55. https://doi.org/10.3892/mco.2020.2125